İzole hipogonadotropik hipogonadizm tanılı erkek hastaların tedavi ile ortaya çıkan klinik, radyolojik ve laboratuvar sonuç değişimlerinin değerlendirilmesi
Yükleniyor...
Dosyalar
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Hatay Mustafa Kemal Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Hipogonadizm, gonadların yetersiz işlev göstermesidir. Gonadal seviyede olan bozukluklar primer, hipotalamo-hipofizer seviyede olan bozukluklar sekonder (hipogonadotropik) hipogonadizm olarak adlandırılır. Çalışmamızın amacı izole hipogonadotropik hipogonadizm tanısı almış hastaların uygulanan tedavilerin etkinliği ve güvenilirliğini gözlemlemektir. Gereç ve Yöntem: Çalışmaya 2016-2020 yılları arasında Hatay Mustafa Kemal Üniversitesi Araştırma Hastanesi Endokrinoloji polikliniğine başvurmuş olan 19-48 yaş aralığındaki izole hipogonadotropik hipogonadizm tanılı ve tedavi başlanmış 53 erkek hasta alındı. Kayıtlar retrospektif olarak incelendi. Hastaların demografik bilgileri, geliş sıklığı, tedavilerin türü ve süresi, laboratuvar ve radyolojik verileri hasta dosyalarından elde edildi.. Bulgular: Sadece testosteron uygulanan hastalarda tedavi sonrasında hct (hematokrit) (p=0,041) ve LDL (düşük yoğunluklu lipoprotein) (p=0,043) düzeyinde artış saptandı. Diğer laboratuvar bulguları ve testis volümleri yönünden anlamlı farklılık saptanmadı. Sadece hCG (human chorionic gonadotropin ) uygulanan hastalarda tedavi sonrasında testosteron (p=0,049) , hct (p=0,049) ve ALT ( alanin aminotransferaz) (p=0,049) düzeyinde artış saptandı. Diğer laboratuvar bulguları ve testis volümleri yönünden anlamlı farklılık saptanmadı. Ardışık ya da farklı zamanlarda testosteron ve hCG uygulanan hastalarda tedavi sonrasında WBC ( White Blood Cell) ( p < 0,001), hb (hemoglobin) (p=0,041), trigliserit (p=0,002), testosteron (p=0,006), FSH ( folikül stimülan hormon) (p=0,02), LH (luteinizan hormon) (p <0,001) düzeyi ve testis volümlerinde (p<0,001) artış; LDL(p<0,001), AST ( aspartat aminotransferaz) (p<0,001), plt (platelet) (p<0,001) düzeyinde azalma saptandı. Diğer laboratuvar bulgularında anlamlı farklılık saptanmadı. Sonuç: İzole Hipogonadotropik Hipogonadizmli hastaların tedavisinde ardışık ya da farklı zamanlarda testosteron ve hCG tedavisi uygulanması sonucu daha olumlu etkiler ve daha az oranda yan etkiler görüldü.
Purpose: Hypogonadism is insufficient function of the gonads. Disorders at the gonadal level are called primary, while those at the hypothalamo-pituitary level are called secondary (hypogonadotropic) hypogonadism. The aim of our study is to observe the efficacy and safety of treatments applied to patients with isolated hypogonadotropic hypogonadism. Materials and Methods: The study included 53 male patients aged 19-48 years who applied to Hatay Mustafa Kemal University Research Hospital Endocrinology outpatient clinic, diagnosed with isolated hypogonadotropic hypogonadism and started treatment. Records were reviewed retrospectively. Demographic information of the patients, frequency of admission, type and duration of treatments, laboratory and radiological data were obtained from patient files. Results: An increase in hct (hematocrit) (p=0.041) and LDL (low-density lipoprotein) (p=0.043) levels was detected in patients who received only testosterone after treatment. No significant difference was found in terms of other laboratory findings and testicular volumes. After the treatment, testosterone (p=0.049), hct (p=0.049) and ALT (alanine aminotransferase) (p=0.049) levels were increased in patients who were administered only hCG (human chorionic gonadotropin). No significant difference was found in terms of other laboratory findings and testicular volumes. WBC (White Blood Cell) ( p < 0.001), hb (hemoglobin) (p=0.041), triglyceride (p=0.002), testosterone (p=0.006), FSH ( increase in follicle stimulating hormone (p=0.02), LH (luteinizing hormone) (p <0.001) level and testicular volumes (p<0.001); LDL(p<0.001), AST (aspartate aminotransferase) (p<0.001), plt (platelet) (p<0.001) levels were decreased. There was no significant difference in other laboratory findings. Conclusion: In the treatment of patients with isolated hypogonadotropic hypogonadism, more positive effects and less side effects were seen as a result of sequential or different times of testosterone and hCG treatment. Key words: Isolated HH, Treatment, Testosterone, Human chorionic gonadotropin.
Purpose: Hypogonadism is insufficient function of the gonads. Disorders at the gonadal level are called primary, while those at the hypothalamo-pituitary level are called secondary (hypogonadotropic) hypogonadism. The aim of our study is to observe the efficacy and safety of treatments applied to patients with isolated hypogonadotropic hypogonadism. Materials and Methods: The study included 53 male patients aged 19-48 years who applied to Hatay Mustafa Kemal University Research Hospital Endocrinology outpatient clinic, diagnosed with isolated hypogonadotropic hypogonadism and started treatment. Records were reviewed retrospectively. Demographic information of the patients, frequency of admission, type and duration of treatments, laboratory and radiological data were obtained from patient files. Results: An increase in hct (hematocrit) (p=0.041) and LDL (low-density lipoprotein) (p=0.043) levels was detected in patients who received only testosterone after treatment. No significant difference was found in terms of other laboratory findings and testicular volumes. After the treatment, testosterone (p=0.049), hct (p=0.049) and ALT (alanine aminotransferase) (p=0.049) levels were increased in patients who were administered only hCG (human chorionic gonadotropin). No significant difference was found in terms of other laboratory findings and testicular volumes. WBC (White Blood Cell) ( p < 0.001), hb (hemoglobin) (p=0.041), triglyceride (p=0.002), testosterone (p=0.006), FSH ( increase in follicle stimulating hormone (p=0.02), LH (luteinizing hormone) (p <0.001) level and testicular volumes (p<0.001); LDL(p<0.001), AST (aspartate aminotransferase) (p<0.001), plt (platelet) (p<0.001) levels were decreased. There was no significant difference in other laboratory findings. Conclusion: In the treatment of patients with isolated hypogonadotropic hypogonadism, more positive effects and less side effects were seen as a result of sequential or different times of testosterone and hCG treatment. Key words: Isolated HH, Treatment, Testosterone, Human chorionic gonadotropin.
Açıklama
Anahtar Kelimeler
İç Hastalıkları, Internal diseases, İzole HH, Tedavi, Testosteron, Human chorionic gonadotropin .
